A-435 Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 88
    AstraZeneca azd4547
    Clinical activity of the FGFR inhibitor <t>AZD4547</t> in FGFR -amplified breast and gastric cancers.
    Azd4547, supplied by AstraZeneca, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/azd4547/product/AstraZeneca
    Average 88 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    azd4547 - by Bioz Stars, 2022-09
    88/100 stars
      Buy from Supplier

    96
    ATCC mda mb 435
    Characterization of M14 using Immunostaining and ABO Analysis. ( a–b ) Representative images of M14 cells in culture. Scale bars, 100 µm. ( c–d ). Immunostaining of M14 cells using a pan‐melanoma antibody cocktail. Antibodies are directed against melanosome (HMB45), MART‐1/Melan A (A103) and tyrosinase (T311). Cells displayed abundant cytoplasm and were multinucleated; some apoptotic cells were noted, as indicated by the arrows. Scale bar in C, 10 µm; scale bar in D, 20 µm. ( e ) ABO sequence demonstrating blood type O. Upper panel, sequence reported previously for A or B alleles and sequence reported for the O allele. 21 Lower panel, forward and reverse sequence from M14 sample (passage 16, derived from passage 15 from December 2, 1975). Identical sequence results were obtained from ML14 and <t>MDA‐MB‐435S</t> samples (data not shown).
    Mda Mb 435, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mda mb 435/product/ATCC
    Average 96 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mda mb 435 - by Bioz Stars, 2022-09
    96/100 stars
      Buy from Supplier

    99
    Thermo Fisher neurotrace 435 455 blue fluorescent nissl stain
    Characterization of M14 using Immunostaining and ABO Analysis. ( a–b ) Representative images of M14 cells in culture. Scale bars, 100 µm. ( c–d ). Immunostaining of M14 cells using a pan‐melanoma antibody cocktail. Antibodies are directed against melanosome (HMB45), MART‐1/Melan A (A103) and tyrosinase (T311). Cells displayed abundant cytoplasm and were multinucleated; some apoptotic cells were noted, as indicated by the arrows. Scale bar in C, 10 µm; scale bar in D, 20 µm. ( e ) ABO sequence demonstrating blood type O. Upper panel, sequence reported previously for A or B alleles and sequence reported for the O allele. 21 Lower panel, forward and reverse sequence from M14 sample (passage 16, derived from passage 15 from December 2, 1975). Identical sequence results were obtained from ML14 and <t>MDA‐MB‐435S</t> samples (data not shown).
    Neurotrace 435 455 Blue Fluorescent Nissl Stain, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/neurotrace 435 455 blue fluorescent nissl stain/product/Thermo Fisher
    Average 99 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    neurotrace 435 455 blue fluorescent nissl stain - by Bioz Stars, 2022-09
    99/100 stars
      Buy from Supplier

    Image Search Results


    Clinical activity of the FGFR inhibitor AZD4547 in FGFR -amplified breast and gastric cancers.

    Journal: Cancer discovery

    Article Title: High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial

    doi: 10.1158/2159-8290.CD-15-1246

    Figure Lengend Snippet: Clinical activity of the FGFR inhibitor AZD4547 in FGFR -amplified breast and gastric cancers.

    Article Snippet: Antibodies used were phosphorylated (p) AKT Ser473 (4058), pAKT T308 (2965), AKT (4691), p4EBP1 T37/46 (2855), 4EBP1 (9452), pERK1/2-Thr202/Tyr204 (4370), ERK1, 2 (9102), EGFR (2232), pEGFR Y1068 (3777), pERBB3 Y1289 (4791), pERBB2 Y1221/1222 (2249), pFGFR Y653/654 (3471), pFRS2a (3864), pIGF1R (3918), IGF1R (9750), p85 PI3K (4292), PIK3CA (4255), PTEN (9559), phospho-ribosomal protein S6 (5364), ribosomal protein S6 (2217; all Cell Signaling Technology); β-Actin (A5441; Sigma); FGFR2 (sc-122), EGFR (sc-03), PARP1 (sc-8003), and FRS2 (sc-8318; Santa Cruz Biotechnology); ERBB3 (ab32121) and FGFR1 (ab76464; Abcam); Grb2 (610111; BD Transduction Laboratories); p85 PI3K (ABS233; Millipore); and AZD4547 and AZD8055 were provided by AstraZeneca.

    Techniques: Activity Assay, Amplification

    Characterization of M14 using Immunostaining and ABO Analysis. ( a–b ) Representative images of M14 cells in culture. Scale bars, 100 µm. ( c–d ). Immunostaining of M14 cells using a pan‐melanoma antibody cocktail. Antibodies are directed against melanosome (HMB45), MART‐1/Melan A (A103) and tyrosinase (T311). Cells displayed abundant cytoplasm and were multinucleated; some apoptotic cells were noted, as indicated by the arrows. Scale bar in C, 10 µm; scale bar in D, 20 µm. ( e ) ABO sequence demonstrating blood type O. Upper panel, sequence reported previously for A or B alleles and sequence reported for the O allele. 21 Lower panel, forward and reverse sequence from M14 sample (passage 16, derived from passage 15 from December 2, 1975). Identical sequence results were obtained from ML14 and MDA‐MB‐435S samples (data not shown).

    Journal: International Journal of Cancer

    Article Title: Authentication of M14 melanoma cell line proves misidentification of MDA‐MB‐435 breast cancer cell line

    doi: 10.1002/ijc.31067

    Figure Lengend Snippet: Characterization of M14 using Immunostaining and ABO Analysis. ( a–b ) Representative images of M14 cells in culture. Scale bars, 100 µm. ( c–d ). Immunostaining of M14 cells using a pan‐melanoma antibody cocktail. Antibodies are directed against melanosome (HMB45), MART‐1/Melan A (A103) and tyrosinase (T311). Cells displayed abundant cytoplasm and were multinucleated; some apoptotic cells were noted, as indicated by the arrows. Scale bar in C, 10 µm; scale bar in D, 20 µm. ( e ) ABO sequence demonstrating blood type O. Upper panel, sequence reported previously for A or B alleles and sequence reported for the O allele. 21 Lower panel, forward and reverse sequence from M14 sample (passage 16, derived from passage 15 from December 2, 1975). Identical sequence results were obtained from ML14 and MDA‐MB‐435S samples (data not shown).

    Article Snippet: In our hands, Y‐specific SNP loci were detected in ML14, but not in M14 or MDA‐MB‐435S.

    Techniques: Immunostaining, Sequencing, Derivative Assay, Multiple Displacement Amplification